medigraphic.com
Medicina Universitaria

2007, Number 36

<< Back Next >>

Med Univer 2007; 9 (36)

Activity of C and S anticoagulant proteins and antithrombin upon diagnosis of acute lymphoblastic leucemia

Pérez JCJ, Vázquez GE, Gómez AD

Language: Spanish
References: 21
Page: 101-104
PDF size: 99.63 Kb.


ABSTRACT

Background: Children with acute lymphoblastic leukemia have an increased risk of suffering thrombotic complications associated to a decreased activity of natural anticoagulant proteins C, S and antithrombin that have been related to treatment, particularly to chemotherapy and central catheter placement.
Objective: To investigate if the activity of these proteins decreases upon diagnosis, before starting chemotherapy and placing a central line. Methods: Functional activity of proteins C, S, and AT was measured in 83 children upon diagnosis of ALL. Patients were clinically followed- up documenting thrombotic events from induction of treatment to remission, with a regimen which included moderate doses of L-asparaginase.
Results: The activity of the anticoagulant proteins upon diagnosis of ALL was within normal range. Although, there was a considerable heterogeneity, it was probably due to the altered rate of liver synthesis. This variation in the activity was not related to the development of thrombosis.
Conclusion: No significant decrease in the functional activity of proteins C, S, and AT, nor were thrombotic episodes found in patients with a new diagnosis of ALL.


REFERENCES

  1. Chabner BA, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, editors. Williams Hematology. 7th ed. New York: McGrawHill, 2006;pp:249-74.

  2. Faderl S, Thall PF, Kantarjian HM, Estrov Z. Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol 2002;117:869-74.

  3. Nowak-Gottl U, Wermes C, Junker R, Koch HG, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 667 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595-9.

  4. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease or treatment. Semin Thromb Hemost 1995;21:390-401.

  5. Ruud E, Holmstrom H, De Lange C, Natvig S, et al. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study. Pediatr Hematol Oncol 2006;3:207-16.

  6. Duval M, Suciu S, Ferster A, Rialland X, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 2002;99:2734-9.

  7. Nowak-Gottl U, Heinecke A, Von Kries R, Nurnberger W, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-72.

  8. Athale UH, Chan AK. Thromoboembolic complications inpediatric hematologic malignancies. Semin Thromb Hemost 2007;33:416-26.

  9. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003;101:2529-33.

  10. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005;129:803-10.

  11. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111:199-212.

  12. Mitchell LG, Andrew M, Hanna K, Abshire T, et al. Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003;97:508-16.

  13. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003;111:125-31.

  14. Hill FG, Richards S, Gibson B, Hann I, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).The UK Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 2004;124:33-46.

  15. Laffan MA, Manning RA. Investigation of a thromobotic tendency. In: Lewis SM, Bain BJ, Bates I, editors. Dacie and Lewis practical haematology, 9th ed. London: Churchill Livingstone 2001;pp:391-413.

  16. Guglielmone HA, Vides MA. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemost 1992;67:46-49.

  17. Laroche P, Plassart V, Amiral J. Rapid quantitative latex immunoassays for diagnosis of thrombotic disorders. Thromb Haemost 1989;62:379-82.

  18. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A (on behalf of the participants of the Latin American Consensus Conference). Report on the Second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom 2006;70:39-44.

  19. Moghrabi A, Levy DE, Asselin B, Barr R, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904.

  20. Oner AF, Gurgey A, Kirazli S, Okur H, Tunc B. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999;33:361-4.

  21. Jaime Perez JC, Gomez Almaguer D. The complex nature of the prothrombotic state in acute lymphoblastic leukemia of childhood. Haematologica 2003;88:ELT25.




2020     |     www.medigraphic.com